ZOLEDRONIC ACID FOR INJECTION CONCENTRATE SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Доступна с:

OMEGA LABORATORIES LIMITED

код АТС:

M05BA08

ИНН (Международная Имя):

ZOLEDRONIC ACID

дозировка:

4MG

Фармацевтическая форма:

SOLUTION

состав:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

1VIAL*5ML

Тип рецепта:

Prescription

Терапевтические области:

BONE RESORPTION INHIBITORS

Обзор продуктов:

Active ingredient group (AIG) number: 0141761002; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2014-02-26

Характеристики продукта

PRODUCT MONOGRAPH
PR
Z
OLEDRONIC
A
CID
F
OR
I
NJECTION
C
ONCENTRATE
4 mg/5 mL zoledronic acid (as zoledronic acid monohydrate)
Bone Metabolism Regulator
Omega Laboratories Limited
Date of Preparation: February 18, 2014
11 177 Hamon
Montreal, Quebec
H3M 3E4
Control No. 158614, 171670
_ _
_Page 2 of 58 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
22
DOSAGE AND ADMINISTRATION
.............................................................................
22
OVERDOSAGE
................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 27
STORAGE AND STABILITY
.........................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
34
PHARMACEUTICAL INFORMATION
.........................................................................
34
CLINICAL TRIALS
.........................................................................................................
35
DETAILED PHARMACOLOGY
..................................................